HS remains a sizable but underdiagnosed market; nearly 53% are moderate-to-severe (Hurley II/III) in G7. Treatment continues to escalate with severity, but real-world sequencing is heavily shaped by reimbursement and access constraints. The HS pipeline is becoming increasingly diverse, spanning oral, topical, and subcutaneous therapies that target a broad range of inflammatory pathways. 
Emerging therapies are expected to at least match and ideally surpass IL-17 inhibitors’ clinical benefit while also delivering deeper lesion reduction (HiSCR75/HiSCR90), improved pain control, fewer flares and tunnels, and meaningful gains in quality of life. There are currently no specifically approved therapies for mild HS; topical ruxolitinib (Opzelura) is being developed as a targeted option for Hurley I/II without draining tunnels and can potentially serve as an adjunct to systemic therapy.

This Datamonitor Healthcare report contains a Disease Analysis module.